HK Stock Market Move | VIVA BIOTECH (01873) surged over 20% in the afternoon. VIVA BIOTECH recently entered into an AI-driven reverse target discovery R&D collaboration with Jilin Province Xidian Pharmaceutical Sci-Tech Development.

VIVA BIOTECH (01873) surged over 20% in the afternoon. As of press time, it rose 19.59% to HK$1.77, with a turnover of HK$32.0124 million. On the news front, VIVA BIOTECH recently entered into an AI-driven reverse target discovery R&D collaboration with Jilin Province Xidian Pharmaceutical Sci-Tech Development. Leveraging VIVA BIOTECH's Mol2MARS platform, the two parties conducted systematic research on the potential mechanisms of action and targets of drug molecules, building an innovative target discovery R&D closed loop of "AI computing + experimental validation," providing new scientific basis for the analysis of drug mechanisms of action and expansion of indications. CMSC pointed out that as of the first half of 2026, CADD/AIDD had cumulatively participated in 228 projects and served 92 procurement clients; revenue from AI-empowered projects accounted for approximately 14.0% of CRO revenue, and revenue from wet lab experiments related to AI clients accounted for approximately 15.0%. The company upgraded and launched the MARS multimodal comprehensive algorithm platform, building significant technical barriers in the fields of peptides, cyclic peptides, and complex macrocyclic compounds, and comprehensively upgraded its three underlying modules.